Evaluation of efficacy of Ayurvedic formulation in painful menstruation

Clinical evaluation of Jeerakadi Modaka and dashmoola Taila matra Basti in the management of Kashtaartava wsr to primary dysmenorrhoea

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/12/029707

Enrollment

Registered

2020-12-10

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N00-N99- Diseases of the genitourinary system

Interventions

Intervention1: Jeerakadi Modaka. : Dose â?? 10 gms twice a day for three consecutive menstrual cycles Intervention2: Dashmoola Taila Matra Basti: Matra Basti of Dashmoola Taila in 60 ml dose for succe

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects coming with chief complaint of Kashatartava with or without associated symptoms. 2. Subjects in age group of 16 to 35 years. 3. Subjects with H/O using analgesics during menses. 4. Subjects suffering with Kashtartava for more than 2 consecutive cycles.

Exclusion criteria

Exclusion criteria: 1. Subjects below 16 & above 35 years of age. 2. Subjects suffering from secondary dysmenorrhoea. 3. Subjects suffering from diseases like veneral diseases, PID etc. 4. Subjects suffering from metabolic diseases such as D.M., T.B. 5. Subjects having organic pathology of uterus and adnexae e.g. Fibroid uterus, carcinoma of endometrium etc. 6. Subjects using intra uterine contraceptive devices. 7. Subjects having pain abdomen associated with metrorrhagia. 8. Subjects with H/O hypothyroidism and hyperthyroidism with DUB.

Design outcomes

Primary

Measure	Time frame
1. To assess the efficacy of Jeerakadi Modaka and Dashmoola Taila Matra Basti in the management of dysmenorrhoea. 2. To assess the efficacy of trial drugs on subjective parameters like Pain intensity, menstrual blood flow, amount of blood loss, VAS scale, WaLIDD score. 3.Timepoint: Clinical assessment will be done after each menstrual cycle during trial. Final assessment will be done after completion of trial of 3 consecutive menstrual cycles. Case will be followed after one menstrual cycle of completion of trial without any medication. During trial- 2 follow ups After trial- 1 follow up	—

Measure

Time frame

1. To assess the efficacy of Jeerakadi Modaka and Dashmoola Taila Matra Basti in the management of dysmenorrhoea. 2. To assess the efficacy of trial drugs on subjective parameters like Pain intensity, menstrual blood flow, amount of blood loss, VAS scale, WaLIDD score. 3.Timepoint: Clinical assessment will be done after each menstrual cycle during trial. Final assessment will be done after completion of trial of 3 consecutive menstrual cycles. Case will be followed after one menstrual cycle of completion of trial without any medication. During trial- 2 follow ups After trial- 1 follow up

—

Secondary

Measure	Time frame
To assess the efficacy of Jeerakadi Modaka and Dashmoola Taila Matra Basti in the management of dysmenorrhoeaTimepoint: 3 consecutive menstrual cycle	—

Countries

India

Contacts

Public ContactDr Shikha Sharma

state ayurvedic college and hospital

bedar.shashi@gmail.com7068364242

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026